12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

MolecularMD BCR-ABL T315I Mutation Test regulatory update

MolecularMD voluntarily withdrew a PMA to FDA for its MolecularMD BCR-ABL T315I Mutation Test, a companion diagnostic for Ariad's cancer compound ponatinib to identify chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who have...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >